O papel do farmacêutico na discussão sobre intercambialidade no tratamento de câncer de mama com Trastuzumabe

• Autor(a) principal: Cardoso, Elisângela Santos Silva
• Data de Publicação: 2021
• Outros Autores: Silva, José Helio Jesus da, Santos, Julio Cesar Ribeiro dos, Santos, Karina Alves dos, Silva, Rafael Sant' Ana da, Francisco, Renan Vinícius Ferreira da Silva, Oliveira, Adriano dos Santos de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório do Centro Universitário Braz Cubas
• Texto Completo: https://repositorio.cruzeirodosul.edu.br/handle/123456789/3437
• topic: Anticorpos monoclonais; Medicamentos biossimilares; Produtos biológicos; CNPQ::CIENCIAS DA SAUDE::FARMACIA

Monoclonal antibodies are biological drugs used for various treatments, including cancer treatments. Due to this great use, biological laboratories invest in this type of medicine, producing molecules similar to those already launched on the market, and are called biosimilar medicines. For breast cancer with a positive diagnosis for the HER2 type, the monoclonal antibody Trastuzumab is indicated because it has few side effects, acting directly on tumor cells and sparing healthy cells, with great efficiency in its use. It was the first biosimilar monoclonal antibody approved in Brazil, increasing access to treatment, especially in the national health service (SUS). As cancer treatment is usually long, the patient may face the practice of interchangeability, which is the replacement of the reference drug for their own biosimilar during therapy. The role of the pharmacist is essential to guide issues related to this practice and monitor pharmacovigilance and post-marketing data, ensuring qualified assistance to patients who face it.